Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose LevelsPatients are Now Be ...
Studies of germline genetic testing programs provide a snapshot of challenges at academic and community practices at the NSGC annual meeting.
This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...
Aptose Biosciences Inc. Net loss for the quarter ended September 30, 2025 decreased by $1.8 million to $5.1 million, as compared to $7.0 million for the comparable period in 2024. Net loss for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback